Your browser is no longer supported. Please, upgrade your browser.
Settings
NMTR [NASD]
9 Meters Biopharma, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own0.90% Shs Outstand141.63M Perf Week-5.23%
Market Cap331.30M Forward P/E- EPS next Y-0.11 Insider Trans48.16% Shs Float116.68M Perf Month17.27%
Income-65.40M PEG- EPS next Q-0.04 Inst Own31.20% Short Float3.12% Perf Quarter52.34%
Sales- P/S- EPS this Y16.80% Inst Trans110.87% Short Ratio0.32 Perf Half Y169.33%
Book/sh0.03 P/B54.33 EPS next Y78.00% ROA-704.10% Target Price- Perf Year171.67%
Cash/sh0.06 P/C26.72 EPS next 5Y- ROE- 52W Range0.37 - 2.26 Perf YTD89.76%
Dividend- P/FCF- EPS past 5Y43.20% ROI- 52W High-27.88% Beta-3.81
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low340.42% ATR0.20
Employees8 Current Ratio1.30 Sales Q/Q- Oper. Margin- RSI (14)48.67 Volatility9.94% 12.65%
OptionableYes Debt/Eq0.36 EPS Q/Q77.10% Profit Margin- Rel Volume0.29 Prev Close1.74
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume11.31M Price1.63
Recom1.60 SMA20-9.91% SMA5016.95% SMA20090.21% Volume3,309,977 Change-6.32%
Mar-01-21 07:30AM  
Feb-10-21 07:30AM  
Feb-04-21 08:12AM  
Feb-03-21 07:30AM  
Feb-01-21 07:30AM  
Jan-05-21 12:41PM  
Dec-21-20 07:30AM  
Dec-15-20 04:00PM  
Dec-11-20 08:30AM  
Dec-09-20 07:30AM  
Dec-07-20 07:30AM  
Dec-02-20 11:01AM  
Nov-16-20 07:30AM  
01:51AM  
Nov-09-20 07:30AM  
Nov-02-20 08:00AM  
Sep-08-20 08:30AM  
Aug-31-20 08:30AM  
Aug-13-20 04:30PM  
Aug-12-20 04:30PM  
Aug-04-20 09:30AM  
Jul-28-20 07:30AM  
Jul-21-20 07:45AM  
Jul-13-20 10:26AM  
Jul-06-20 04:15PM  
Jul-02-20 07:30AM  
Jun-29-20 07:30AM  
Jun-24-20 04:05PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 06:30AM  
May-04-20 05:30PM  
9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sirgo Mark ADirectorDec 15Buy0.65230,769150,000774,066Dec 17 04:17 PM
Temperato JohnChief Executive OfficerDec 15Buy0.65153,846100,000977,522Dec 17 04:17 PM
Sitar Edward JChief Financial OfficerDec 15Buy0.6561,53840,000129,338Dec 17 04:17 PM
Sirgo Mark ADirectorSep 11Buy0.6521,48514,00421,485Sep 14 08:06 AM
Sirgo Mark ADirectorSep 11Buy0.6877,00052,360538,784Sep 14 08:06 AM
Sirgo Mark ADirectorSep 10Buy0.6050,00030,000461,784Sep 14 08:06 AM
Temperato JohnChief Executive OfficerAug 21Buy0.6970,00048,300615,496Aug 24 07:01 AM
Constantino Michael T.DirectorAug 20Buy0.7534,10825,58134,108Aug 21 04:20 PM
Sirgo Mark ADirectorAug 17Buy0.56100,00056,000411,784Aug 18 05:19 PM
Temperato JohnChief Executive OfficerAug 17Buy0.5735,00019,831545,496Aug 17 04:18 PM